Product Description
Abarelix is a polypeptide compound composed of ten natural and non-natural amino acid resiudes in a linear sequence. It has a role as a hormone antagonist and an antineoplastic agent.
Mechanisms of Action: GnRH Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Germany | Sweden
Approved Indications: None
Known Adverse Events: None
Company: PRAECIS
Company Location: WALTHAM MA 02451
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ABACAS1 | P3 |
Completed |
Prostate Cancer |
2001-02-01 |
|
| 149-IV-01 | P4 |
Suspended |
Prostate Cancer |
None |
|
| NCT00100243 | P2 |
Completed |
Prostate Cancer |
None |